Dexcom’s new genAI platform shows users how their behaviors affect their glucose levels

The news: Dexcom launched a generative AI (genAI) platform that analyzes data from users’ wearable biosensors to help them better understand how their lifestyle behaviors affect their glucose levels.

Dexcom says it’s the first continuous glucose monitor (CGM) manufacturer to integrate genAI into glucose biosensing tech.

How it works: Developed using Google Cloud’s Vertex AI platform and Gemini models, Dexcom’s platform is designed to be used with Stelo, its FDA-approved over-the-counter (OTC) CGM.

After analyzing users’ health data patterns, the platform provides them with actionable insights on how to improve their metabolic health right in the Stelo app. This includes personalized tips, recommendations, and educational content related to exercise, diet, and sleep.

Our take: Dexcom’s decision is smart business, considering the increased interest among consumers to track their health and wellness and receive actionable information to improve on.

  • Using CGMs to track blood sugar levels has become a popular trend among wellness enthusiasts, per an August 2024 Business Insider article.

More importantly, Dexcom is likely using the integration as a proving ground for the platform where it can work out any kinks before introducing it to the litany of diabetic patients who use the company’s legacy CGM products.

Who’s next? In June, Dexcom rival Abbott received FDA clearance for its over-the-counter CGM system Lingo, which is designed for those without diabetes.

Lingo is currently able to provide personalized insights and coaching through an app that interprets its biosensor readings. We expect Abbott’s Lingo to be the next such product equipped with an accompanying genAI platform.

This article is part of EMARKETER’s client-only subscription Briefings—daily newsletters authored by industry analysts who are experts in marketing, advertising, media, and tech trends. To help you finish 2024 strong, and start 2025 off on the right foot, articles like this one—delivering the latest news and insights—are completely free through January 31, 2025. If you want to learn how to get insights like these delivered to your inbox every day, and get access to our data-driven forecasts, reports, and industry benchmarks, schedule a demo with our sales team.